InvestorsHub Logo
Followers 22
Posts 1558
Boards Moderated 0
Alias Born 01/23/2014

Re: None

Tuesday, 12/24/2019 9:45:29 AM

Tuesday, December 24, 2019 9:45:29 AM

Post# of 1121
B. Riley analyst Mayank Mamtani says Acasti Pharma's (NASDAQ:ACST) 24% pullback yesterday was "unwarranted" as the delay in CaPre drug data is likely "inconsequential" to the anticipated study results.

Yesterday, Acasti announced it will now report top-line results for the Trilogy 1 Phase 3 trial in January 2020 due to an unexpected delay in data processing.

Mamtani also notes ACST's "incrementally improved balance sheet," which limits the "post-data financing overhang."

B. Riley maintains a Buy rating and $8 PT on ACST. The company has a Very Bullish average Sell Side rating.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News